SAN FRANCISCO, Oct.
1, 2015 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:
NKTR) today announced that it will host a Research and Development
(R&D) Day for analysts and investors on Thursday, October 8, 2015. The event is
scheduled to take place from 12:30 - 3:30
p.m. Eastern Time in New York
City, and will be simultaneously streamed as a webcast.
The event will focus on the Company's internally-discovered
R&D programs with leading experts presenting, including:
- Michael Atkins, M.D., Deputy
Director of the Georgetown-Lombardi Comprehensive Cancer Center,
Professor of Oncology and Medicine (Hematology/Oncology),
Georgetown University School of
Medicine
- Adi Diab, M.D., Assistant
Professor, Department of Melanoma Medical Oncology, Division of
Cancer Medicine, The University of
Texas MD Anderson Cancer Center
- Naiyer Rizvi, M.D., Director of
Thoracic Oncology and Director of Immunotherapeutics, Columbia University Medical Center
- Martin Hale, M.D., Medical
Director, Gold Coast Research, LLC
- Jack Henningfield, Ph.D., Vice
President, Research, Health Policy, & Abuse Liability,
PinneyAssociates
To RSVP for this event in person, please contact Jamie Maarten at Argot Partners. A link to the
live audio webcast of this presentation and accompanying slides may
be accessed by visiting the "Investor Relations" section of the
Nektar website at www.nektar.com. The webcast replay of the
presentation will be archived in the "Investor Relations" section
of the Nektar website following the event for 30 days.
About Nektar
Nektar Therapeutics has a robust R&D pipeline in pain,
oncology, hemophilia and other therapeutic areas. In the area of
pain, Nektar has an exclusive worldwide license agreement with
AstraZeneca for MOVANTIK™ (naloxegol), the first FDA-approved
once-daily oral peripherally-acting mu-opioid receptor antagonist
(PAMORA) medication for the treatment of opioid-induced
constipation (OIC), in adult patients with chronic, non-cancer
pain. The product is also approved in the European Union as
MOVENTIG® (naloxegol) and is indicated for adult patients with
OIC who have had an inadequate response to laxatives. The
AstraZeneca agreement also includes NKTR-119, an earlier stage
development program that is a co-formulation of MOVANTIK and an
opioid. NKTR-181, a wholly-owned mu-opioid analgesic molecule for
chronic pain conditions, is in Phase 3 development. NKTR-171, a
wholly-owned new sodium channel blocker being developed as an oral
therapy for the treatment of peripheral neuropathic pain, is in
Phase 1 clinical development. In hemophilia,
ADYNOVATE™ [Antihemophilic Factor (Recombinant)], a
longer-acting PEGylated Factor VIII therapeutic has been filed for
approval in the US by partner, Baxalta Inc. In anti-infectives,
Amikacin Inhale is in Phase 3 studies conducted by Bayer Healthcare
as an adjunctive treatment for intubated and mechanically
ventilated patients with Gram-negative pneumonia.
Nektar's technology has enabled nine approved products in the
U.S. or Europe through
partnerships with leading biopharmaceutical companies, including
AstraZeneca's MOVANTIK™, UCB's Cimzia® for Crohn's disease and
rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's
Neulasta® for neutropenia.
Nektar is headquartered in San
Francisco, California, with additional operations in
Huntsville, Alabama and
Hyderabad, India. Further
information about the company and its drug development programs and
capabilities may be found online at http://www.nektar.com.
MOVANTIK™ is a trademark and MOVENTIG® is a registered trademark
of the AstraZeneca group of companies.
ADYNOVATE is a trademark of Baxalta Inc.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements can be identified by words such
as: "anticipate," "intend," "plan," "expect," "believe," "should,"
"may," "will" and similar references to future periods. Examples of
forward-looking statements include, among others, statements we
make regarding the potential of partnered drugs and drug
candidates and our research and development pipeline.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, anticipated
events and trends, the economy and other future conditions. Because
forward-looking statements relate to the future, they are subject
to inherent uncertainties, risks and changes in circumstances that
are difficult to predict and many of which are outside of our
control. Our actual results may differ materially from those
indicated in the forward-looking statements. Therefore, you should
not rely on any of these forward-looking statements. Important
factors that could cause our actual results to differ materially
from those indicated in the forward-looking statements include,
among others, (i) our drug candidates and those of our
collaboration partners are in various stages of clinical
development and the risk of failure is high and can unexpectedly
occur at any stage prior to regulatory approval for numerous
reasons including safety and efficacy findings even after positive
findings in previous preclinical and clinical studies; (ii) the
timing of the commencement or end of clinical trials and the
commercial launch of drugs may be delayed or unsuccessful due to
regulatory delays, slower than anticipated patient enrollment,
manufacturing challenges, changing standards of care, evolving
regulatory requirements, clinical trial design, clinical outcomes,
competitive factors, or delay or failure in ultimately obtaining
regulatory approval in one or more important markets; (iii)
scientific discovery of new medical breakthroughs is an inherently
uncertain process and the future success of the application of our
technology platform to potential new drug candidates is therefore
highly uncertain and unpredictable and one or more research and
development programs could fail; (iv) patents may not issue from
our patent applications for our drugs and drug candidates, patents
that have issued may not be enforceable, or additional intellectual
property licenses from third parties may be required; and (v) the
outcome of any existing or future intellectual property or other
litigation related to our drugs and drug candidates and those of
our collaboration partners. Other important risks and
uncertainties set forth in our Annual Report on Form 10-Q filed
with the Securities and Exchange
Commission on August 6, 2015. Any forward-looking
statement made by us in this press release is based only on
information currently available to us and speaks only as of the
date on which it is made. We undertake no obligation to update any
forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise.
Contact:
Investors
Argot Partners
Jamie Maarten
(646) 351-0937
jamie@argotpartners.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nektar-to-host-research--development-day-for-analysts-and-investors-on-october-8th-300152248.html
SOURCE Nektar Therapeutics